Literature DB >> 26022167

Tuberous sclerosis complex.

Francis J DiMario1, Mustafa Sahin2, Darius Ebrahimi-Fakhari3.   

Abstract

Tuberous sclerosis complex is an autosomal-dominant, neurocutaneous, multisystem disorder characterized by cellular hyperplasia and tissue dysplasia. The genetic cause is mutations in the TSC1 gene, found on chromosome 9q34, and TSC2 gene, found on chromosome 16p13. The clinical phenotypes resulting from mutations in either of the 2 genes are variable in each individual. Herein, advances in the understanding of molecular mechanisms in tuberous sclerosis complex are reviewed, and current guidelines for diagnosis, treatment, follow-up, and management are summarized. Published by Elsevier Inc.

Entities:  

Keywords:  Autism; Epilepsy; Mechanistic target of rapamycin (mTOR); Neurocutaneous; Neurogenetic; Rapamycin; Subependymal giant cell astrocytoma; Tuberous sclerosis complex

Mesh:

Substances:

Year:  2015        PMID: 26022167     DOI: 10.1016/j.pcl.2015.03.005

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  28 in total

1.  Hypothalamic orexin and mechanistic target of rapamycin activation mediate sleep dysfunction in a mouse model of tuberous sclerosis complex.

Authors:  Bo Zhang; Dongjun Guo; Lirong Han; Nicholas Rensing; Akiko Satoh; Michael Wong
Journal:  Neurobiol Dis       Date:  2019-10-09       Impact factor: 5.996

Review 2.  Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism.

Authors:  Darius Ebrahimi-Fakhari; Afshin Saffari; Lara Wahlster; Jenny Lu; Susan Byrne; Georg F Hoffmann; Heinz Jungbluth; Mustafa Sahin
Journal:  Brain       Date:  2015-12-29       Impact factor: 13.501

3.  Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex.

Authors:  Darius Ebrahimi-Fakhari; Afshin Saffari; Lara Wahlster; Alessia Di Nardo; Daria Turner; Tommy L Lewis; Christopher Conrad; Jonathan M Rothberg; Jonathan O Lipton; Stefan Kölker; Georg F Hoffmann; Min-Joon Han; Franck Polleux; Mustafa Sahin
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

Review 4.  Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.

Authors:  Kim M Keppler-Noreuil; Victoria E R Parker; Thomas N Darling; Julian A Martinez-Agosto
Journal:  Am J Med Genet C Semin Med Genet       Date:  2016-11-18       Impact factor: 3.908

5.  The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.

Authors:  Bo Zhang; Jia Zou; Lirong Han; Brennan Beeler; Joseph L Friedman; Elizabeth Griffin; Yue-Shan Piao; Nicholas R Rensing; Michael Wong
Journal:  Epilepsia       Date:  2018-08-05       Impact factor: 5.864

6.  Microglial activation during epileptogenesis in a mouse model of tuberous sclerosis complex.

Authors:  Bo Zhang; Jia Zou; Lirong Han; Nicholas Rensing; Michael Wong
Journal:  Epilepsia       Date:  2016-06-06       Impact factor: 5.864

7.  Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.

Authors:  Anna Jeong; Michael Wong
Journal:  J Child Neurol       Date:  2017-03-16       Impact factor: 1.987

8.  Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner.

Authors:  Jia Zou; Bo Zhang; David H Gutmann; Michael Wong
Journal:  Epilepsia       Date:  2017-10-12       Impact factor: 5.864

9.  Fetal and maternal manifestations of tuberous sclerosis complex: Value of fetal MRI.

Authors:  Reema Goel; Nishant Aggarwal; Monica E Lemmon; Thangamadhan Bosemani
Journal:  Neuroradiol J       Date:  2016-02-02

10.  Pattern of TSC1 and TSC2 germline mutations in Russian patients with tuberous sclerosis.

Authors:  Evgeny N Suspitsin; Grigoriy A Yanus; Marina Yu Dorofeeva; Tatiana A Ledashcheva; Nataliya V Nikitina; Galina V Buyanova; Elena V Saifullina; Anna P Sokolenko; Evgeny N Imyanitov
Journal:  J Hum Genet       Date:  2018-02-23       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.